Go or no go? Key FDA decisions for Argenx and Regeneron
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
Go or no go? Seagen's Padcev eyes FDA approval
Seres and Pfizer are also set for upcoming FDA Pdufa decisions, and a panel is scheduled for Astrazeneca and Merck’s Lynparza.
The ink dries on the blank cheque craze
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
Newamsterdam braves the Spac track
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.